There are currently 7 active clinical trials seeking participants for Melanoma (Skin) research studies. The states with the highest number of trials for Melanoma (Skin) participants are Ohio, Illinois, Minnesota and Michigan.
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT06298734
Recruiting
The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy. The names of the groups in this research study are: * High-Intensity Exercise (EX) * High-fiber Diet (DT) * Combined High-Intensity Exercise and High-Fiber Diet (COMB) * Attention Control (AC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Melanoma (Skin), Skin Cancer, Advanced Melanoma
Register for Updates
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Biogenix Molecular, Miami, Florida +9 locations
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Birmingham Alabama, Birmingham, Alabama +52 locations
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT06771544
Recruiting
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
Conditions: Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
Register for Updates
Rural Adult and Youth Sun Protection Study
NCT06439979
Recruiting
The purpose of this study is to help prevent skin cancer by improving the use of sun protective behaviors among youths living in rural communities in Utah and West Virginia.
Gender:
ALL
Ages:
Between 3 years and 7 years
Trial Updated:
12/12/2024
Locations: University of Utah, Salt Lake City, Utah +1 locations
Conditions: Melanoma (Skin), Skin Cancer
Register for Updates
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647
Recruiting
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Melanoma (Skin)
Register for Updates
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550
Recruiting
The goal of this study is to observe metabolic features associated with human melanoma tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Melanoma (Skin)
Register for Updates